SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SMART-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SMART-101 overview
SMART-101 is under development for the treatment of acute lymphocytic leukemia, acute myeloid leukemia, relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome. The therapeutic candidate is developed based on ex vivo thymus platform that differentiates CD34 positive stem cells purified from cord blood or peripheral hematopoietic stem cells into T Cell Progenitors so-called ProTcell. It is administered through intravenous route.
Smart Immune overview
Smart Immune is a biotechnology company that is engaged in developing cell therapy for threatening diseases such as high-risk blood cancers and primary immunodeficiencies. The company is headquartered in Paris, Ile-de-France, France.
For a complete picture of SMART-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
